Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 53.09
-1.59 (-2.91%)
Apr 28, 2026, 3:04 PM CST
SHE:002294 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 4,383 | 4,216 | 3,910 | 3,280 | 3,401 | 3,020 |
Other Revenue | 136.37 | 136.37 | 102.73 | 85.67 | 81.27 | 38.73 |
| 4,519 | 4,353 | 4,012 | 3,365 | 3,482 | 3,058 | |
Revenue Growth (YoY) | 13.44% | 8.48% | 19.22% | -3.35% | 13.85% | 11.68% |
Cost of Revenue | 1,131 | 1,105 | 1,138 | 1,065 | 1,001 | 811.29 |
Gross Profit | 3,388 | 3,248 | 2,874 | 2,300 | 2,481 | 2,247 |
Selling, General & Admin | 2,108 | 2,031 | 1,745 | 1,302 | 1,332 | 1,340 |
Research & Development | 562.52 | 539.33 | 421.24 | 409.19 | 533.75 | 357.37 |
Other Operating Expenses | 43.25 | 32.3 | 18.87 | 20.2 | 46.93 | 44.98 |
Operating Expenses | 2,718 | 2,607 | 2,190 | 1,734 | 1,916 | 1,743 |
Operating Income | 670.52 | 640.47 | 683.83 | 565.82 | 565.58 | 504.3 |
Interest Expense | -21.51 | -21.69 | -16.17 | -17.37 | -12.54 | -10.53 |
Interest & Investment Income | 103.76 | 105.94 | 80.09 | 80.94 | 151.26 | 181.9 |
Currency Exchange Gain (Loss) | -10.48 | -10.48 | 1.69 | 3.01 | 5.55 | -5.78 |
Other Non Operating Income (Expenses) | -1.84 | -0.7 | -1.37 | -0.43 | -5.84 | -7.54 |
EBT Excluding Unusual Items | 740.44 | 713.54 | 748.06 | 631.96 | 704 | 662.35 |
Impairment of Goodwill | - | - | - | -49.61 | -26.61 | - |
Gain (Loss) on Sale of Investments | 37.35 | 36.72 | 14.51 | 8.09 | 3.81 | - |
Gain (Loss) on Sale of Assets | -3.03 | -3.03 | -0.15 | -0.48 | -0.18 | -1.3 |
Asset Writedown | -151.88 | -151.86 | -159.64 | -2.89 | -24.06 | -131.6 |
Other Unusual Items | 60.54 | 60.54 | 29.73 | 54.68 | 56.76 | 70.39 |
Pretax Income | 683.42 | 655.91 | 632.52 | 641.76 | 713.73 | 599.84 |
Income Tax Expense | 7.67 | 3.12 | 27.36 | 60.93 | 79.36 | 71.52 |
Earnings From Continuing Operations | 675.75 | 652.78 | 605.16 | 580.83 | 634.37 | 528.32 |
Minority Interest in Earnings | 0.7 | -1.28 | -3.59 | -0.76 | 2.73 | 5.41 |
Net Income | 676.45 | 651.5 | 601.57 | 580.07 | 637.09 | 533.73 |
Net Income to Common | 676.45 | 651.5 | 601.57 | 580.07 | 637.09 | 533.73 |
Net Income Growth | 12.44% | 8.30% | 3.71% | -8.95% | 19.37% | 776.90% |
Shares Outstanding (Basic) | 1,127 | 1,123 | 1,114 | 1,116 | 1,098 | 1,067 |
Shares Outstanding (Diluted) | 1,127 | 1,123 | 1,114 | 1,116 | 1,098 | 1,067 |
Shares Change (YoY) | 1.13% | 0.83% | -0.13% | 1.55% | 2.90% | 5.23% |
EPS (Basic) | 0.60 | 0.58 | 0.54 | 0.52 | 0.58 | 0.50 |
EPS (Diluted) | 0.60 | 0.58 | 0.54 | 0.52 | 0.58 | 0.50 |
EPS Growth | 11.18% | 7.41% | 3.85% | -10.35% | 16.00% | 733.33% |
Free Cash Flow | 32.93 | 78.34 | 561.45 | 168.44 | 371.84 | 702.48 |
Free Cash Flow Per Share | 0.03 | 0.07 | 0.50 | 0.15 | 0.34 | 0.66 |
Dividend Per Share | 0.550 | 0.550 | 0.500 | 0.500 | 0.500 | 0.400 |
Dividend Growth | 10.00% | 10.00% | - | - | 25.00% | - |
Gross Margin | 74.98% | 74.61% | 71.64% | 68.34% | 71.26% | 73.47% |
Operating Margin | 14.84% | 14.71% | 17.04% | 16.81% | 16.24% | 16.49% |
Profit Margin | 14.97% | 14.97% | 14.99% | 17.24% | 18.30% | 17.45% |
Free Cash Flow Margin | 0.73% | 1.80% | 13.99% | 5.00% | 10.68% | 22.97% |
EBITDA | 1,065 | 1,029 | 1,046 | 893.22 | 873.67 | 798.4 |
EBITDA Margin | 23.58% | 23.64% | 26.08% | 26.54% | 25.09% | 26.11% |
D&A For EBITDA | 394.91 | 388.43 | 362.51 | 327.4 | 308.09 | 294.1 |
EBIT | 670.52 | 640.47 | 683.83 | 565.82 | 565.58 | 504.3 |
EBIT Margin | 14.84% | 14.71% | 17.04% | 16.81% | 16.24% | 16.49% |
Effective Tax Rate | 1.12% | 0.48% | 4.33% | 9.50% | 11.12% | 11.92% |
Revenue as Reported | 4,519 | 4,353 | 4,012 | 3,365 | 3,482 | 3,058 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.